ELVN-001

DRUG2 trials

Sponsors

Enliven Therapeutics

Conditions

CML (Chronic Myelogenous Leukemia)Chronic Myeloid LeukemiaChronic Phase CMLChronic Phase Chronic Myeloid Leukemia, BCR-ABL1 PositiveCml

Phase 1

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

RecruitingNCT05304377

Enliven TherapeuticsChronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml

Start: 2022-05-22End: 2027-12-01Target: 250Updated: 2026-04-01

ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants

RecruitingNCT06787144

Enliven TherapeuticsChronic Phase CML, CML (Chronic Myelogenous Leukemia)

Start: 2025-01-23End: 2028-01-31Target: 21Updated: 2025-07-01

Related Papers

Preliminary safety and efficacy of ELVN-001, a selective active site inhibitor of BCR::ABL1, in patients with CML driven by atypical fusion transcripts

Blood2025-11-031 citations

P683: TRIALS IN PROGRESS: FIRST-IN-HUMAN STUDY OF ELVN-001, A SELECTIVE BCR::ABL1 TYROSINE KINASE INHIBITOR, IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WHO FAILED PREVIOUS TYROSINE KINASE INHIBITOR THERAPIES

HemaSphere2023-08-011 citations

First-in-Human Study of Elvn-001, a Highly Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients with Chronic Myeloid Leukemia Who Failed Previous Tyrosine Kinase Inhibitor Therapies

Blood2022-11-151 citations